Verywell Health on MSN
New diabetic macular edema treatment cuts monthly eye injections to twice a year
Fact checked by Jennifer Klump Key Takeaways Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections.Diabetic ...
Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.
People with diabetic macular edema may get eye injections to help control their symptoms. These eye injections can improve vision and also stop the damage that causes vision to get worse. Most of ...
People with diabetic macular edema may receive eye injections to help control their symptoms. These shots can help to improve vision and also stop the damage that causes vision issues to get worse.
Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting
Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
Australians living with macular degeneration fear they could be left thousands of dollars out of pocket — or risk losing ...
Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...
A funding shortfall for a key copay assistance program to help make eye injections more affordable for low-income patients has caused widespread disruption in treatment, researchers have found. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results